Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update

Enliven Therapeutics, Inc. (NASDAQ:ELVN) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 6,910,000 shares, a growth of 6.1% from the October 15th total of 6,510,000 shares. Based on an average daily trading volume, of 236,300 shares, the short-interest ratio is presently 29.2 days. Approximately 23.8% of the company’s shares are sold short.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded up $0.57 during mid-day trading on Tuesday, reaching $25.47. The company’s stock had a trading volume of 129,477 shares, compared to its average volume of 259,568. The stock has a 50-day moving average of $26.32 and a two-hundred day moving average of $24.05. The stock has a market capitalization of $1.24 billion, a P/E ratio of -13.16 and a beta of 1.08. Enliven Therapeutics has a 1-year low of $9.80 and a 1-year high of $30.03.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 4,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $22.54, for a total value of $95,795.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $22.89, for a total transaction of $274,680.00. Following the transaction, the chief executive officer now owns 1,049,255 shares of the company’s stock, valued at $24,017,446.95. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,195 shares of company stock valued at $4,091,454 in the last quarter. Company insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ELVN. Janus Henderson Group PLC increased its position in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. First Turn Management LLC boosted its position in Enliven Therapeutics by 29.5% during the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock worth $13,666,000 after purchasing an additional 121,849 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares in the last quarter. American Century Companies Inc. grew its holdings in Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after buying an additional 8,540 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Enliven Therapeutics in the 2nd quarter valued at about $322,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ELVN shares. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.